ATOSSA THERAPEUTICS, INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Roger MarshallHouse · R · KS |
ATOSATOSSA THERAPEUTICS, INC. · Stock |
Purchase $1,001 - $15,000 |
Aug 6, 2018 | Oct 25, 2017 | Filing ↗ |
Whale Activity
- Increased6
- New9
- Held14
- Decreased5
- Closed5
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 361.7K | $705K | held |
| BlackRock, Inc. | 168.6K | $329K | increased |
| RENAISSANCE TECHNOLOGIES LLC | 109.9K | $214K | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 95.6K | $186K | increased |
| VANGUARD FIDUCIARY TRUST CO | 52.6K | $103K | held |
| STATE STREET CORP | 39.8K | $78K | held |
| UBS Group AG | 30.5K | $59K | decreased |
| AMERIPRISE FINANCIAL INC | 27.4K | $53K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 21.5K | $42K | increased |
| NORTHERN TRUST CORP | 20.2K | $39K | decreased |
| MILLENNIUM MANAGEMENT LLC | 14.9K | $29K | decreased |
| MORGAN STANLEY | 12.3K | $24K | held |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Steinhart Richard IDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Chen Shu-ChihDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Remmel H. LawrenceDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Finn JonathanDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Galli Stephen JDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Cigler TessaDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Grant / award | +65.0K | $0.00 | $0 | Mar 27, 2026 | Form 4 ↗ |
| Daniel Mark JamesChief Financial Officer | Grant / award | +63.0K | $0.00 | $0 | Mar 26, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Grant / award Amended | +331.7K | $0.00 | $0 | Jan 20, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Grant / award | +325.2K | $0.00 | $0 | Jan 20, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Purchase | +11.2K | $0.88 | $10K | May 21, 2025 | Form 4 ↗ |
| Remmel H. LawrenceDirector | Purchase | +10.0K | $0.70 | $7K | Mar 26, 2025 | Form 4 ↗ |
| Finn JonathanDirector | Purchase | +25.0K | $1.77 | $44K | Apr 10, 2024 | Form 4 ↗ |
| WEAVER GREGORY LFormer EVP, CFO, & Director · Director | Sale | −50.0K | $0.65 | $33K | Nov 15, 2023 | Form 4 ↗ |
| WEAVER GREGORY LEVP & CFO · Director | Purchase | +50.0K | $0.97 | $49K | Jun 20, 2023 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Sale | −107.5K | $5.58 | $600K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Tax withholding | −57.1K | $6.40 | $365K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Option exercise | +70.0K | $1.70 | $119K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Option exercise | +45.0K | $2.52 | $113K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Option exercise | +45.0K | $2.38 | $107K | Jul 2, 2021 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 256.1K | $494K | 0.00% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund COLUMBIA FUNDS SERIES TRUST I | 201.4K | $417K | 0.02% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 99.1K | $191K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 44.7K | $112K | 0.00% | Aug 31, 2026 |
| Columbia Variable Portfolio - Small Cap Value Discovery Fund COLUMBIA FUNDS VARIABLE INSURANCE TRUST | 36.4K | $70K | 0.02% | Jun 30, 2026 |
| iShares Micro-Cap ETF iShares Trust | 29.2K | $56K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 14.4K | $36K | 0.00% | Aug 31, 2026 |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 12.6K | $32K | 0.00% | Aug 31, 2026 |
| U.S. SMALL CAP PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 2,842 | $15K | 0.00% | Apr 30, 2026 |
| U.S. MICRO CAP PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 2,450 | $13K | 0.00% | Apr 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ATOS's shares (CUSIP 04962H704), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
No lobbying filings found naming ATOSSA THERAPEUTICS, INC. as the client.
- DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2021 Q1 · MED$40K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q4 · MED$40K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q3 · MED$40K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q2 · MED$20K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q2 · MED—
Filing ↗
Government Contracts
No federal contract awards found for ATOSSA THERAPEUTICS, INC..
U.S. Patents
No USPTO patent applications found for ATOSSA THERAPEUTICS, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M |
| Diluted EPS | -$4.04 | -$3.04 | -$0.24 | -$0.21 | n/a |
| Operating cash flow | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M |
| Cash and equivalents | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M |
| Shareholders' equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M |
As ATOSSA THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 25, 2026 ↗
Stock Splits
- 1-for-15Reverse splitFeb 2, 2026
- 1-for-12Reverse splitApr 20, 2018
- 1-for-15Reverse splitAug 26, 2016
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 10, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.03, 8.01, 9.01Material agreement · Modification of rights · Other eventsOct 9, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 29, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 7, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementJun 11, 2026
EDGAR ↗ - 8-K · Items 9.01May 8, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 8, 2026
EDGAR ↗

